Skip to content
10-Q

Quarterly Report

REGENEREX PHARMA, INC. RGPX

0001472375-24-000090

← back to feed
Filed
Nov 4, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Nov 4, 2024 278.44M sh
Cash And Equivalents Q2 2024 · Sep 30, 2024 $294
Cash And Equivalents Q2 2024 · Mar 31, 2024 $372
Current Liabilities Q2 2024 · Sep 30, 2024 $4.85M
Current Liabilities Q2 2024 · Mar 31, 2024 $3.84M
Total Liabilities Q2 2024 · Sep 30, 2024 $5.39M
Total Liabilities Q2 2024 · Mar 31, 2024 $4.83M
Current Assets Q2 2024 · Sep 30, 2024 $1.84K
Current Assets Q2 2024 · Mar 31, 2024 $2.91K
Total Assets Q2 2024 · Sep 30, 2024 $632.95K
Total Assets Q2 2024 · Mar 31, 2024 $766.68K
Long Term Debt Q2 2024 · Mar 31, 2024 $184.23K
Operating Cash Flow Q2 2024 · Sep 30, 2023 −$293.29K
Stockholders Equity Q2 2024 · Sep 30, 2023 −$3.63M
Stockholders Equity Q2 2024 · Jun 30, 2023 −$1.08M
Stockholders Equity Q2 2024 · Mar 31, 2023 −$1.12M
Rd Expense Q2 2024 · Sep 30, 2023 $2.4M
Rd Expense Q2 2024 · Sep 30, 2023 $2.4M
Net Income Q2 2024 · Sep 30, 2023 −$2.8M
Net Income Q2 2024 · Sep 30, 2023 −$2.99M
Net Income Q2 2024 · Jun 30, 2023 −$185.58K
Operating Income Q2 2024 · Sep 30, 2023 −$2.79M
Operating Income Q2 2024 · Sep 30, 2023 −$2.95M